Gary Clark: Unfiltered

A joint venture between energy giants Enterprise and ExxonMobil expands NGL pipeline capacity out of the Permian Basin, signaling confidence in long-term growth and intensifying competition in the midstream sector.

SciSparc Ltd. and Clearmind Medicine Inc. are advancing a novel approach to treating depression with a non-hallucinogenic therapy. A recently filed patent application signals a commitment to innovative CNS treatments.

BeOne Medicines is poised to reshape hematological oncology with a diverse pipeline, highlighted by novel BTK degrader BGB-16673 and promising BCL2 inhibitor sonrotoclax. ASH 2025 presentations could be a key catalyst.

Medical device maker Baxter International increased its debt tender offer, suggesting financial strength despite recent earnings volatility and strategic shifts. A deeper look at the company's capital allocation.

Pharmaceutical giant Novartis is doubling down on US manufacturing with a $771M investment in North Carolina, signaling a broader trend of reshoring and bolstering domestic supply chains. The move promises jobs, economic growth, and advanced therapies.

Facing rating downgrades & operational headwinds, Baxter International is restructuring its debt. Is this a sign of strength or a necessary correction? We delve into the company’s financial strategy & industry outlook.

Biotech firm TG Therapeutics secures a spot on Deloitte’s Technology Fast 500, fueled by strong sales of its MS treatment, BRIUMVI. Analysts assess the company's trajectory and potential in a competitive market.

A new partnership aims to extend critical care beyond the hospital walls, leveraging FDA-cleared technology to improve outcomes for vulnerable infants and ease the burden on healthcare systems.

Medical imaging innovator Nanox Imaging acquires VasoHealthcare IT to accelerate US deployment of its AI-powered diagnostics. The deal signals a shift towards integrated solutions in a rapidly evolving market.

Small-cap biotech RenovoRx presents at an investor showcase amid Phase III trial progress and growing competition in targeted cancer therapies. Is the company’s TAMP platform poised for disruption?

Facing a competitive landscape and evolving business model, Vivos Therapeutics is doubling down on direct patient access through strategic acquisitions and expanding its sleep center network. Can this strategy fuel profitability?

Hyperfine receives $3.7M from the Gates Foundation to expand access to brain imaging for infants in resource-constrained settings, leveraging AI and portable MRI technology.

NanoVibronix’s strategic shift to ENvue Medical represents a bold bet on navigation technology. The company is divesting acoustic therapies to focus on improving enteral tube placement and expanding into new applications.

NANO Nuclear Energy’s innovative pump technology is poised to unlock the potential of small modular reactors, promising durable, low-maintenance power for remote locations and beyond. But can the company scale up fast enough?

Positive Phase 3 trial data signals potential for EyePoint Pharmaceuticals’ DURAVYU to revolutionize wet AMD treatment, offering patients a less frequent alternative to monthly injections and a significant market opportunity.

Positive Phase 3 results for Agios' mitapivat in sickle cell disease are tempered by a lack of statistical significance in pain crisis reduction. Analysts weigh the implications for the rare disease drug developer.

A strategic partnership allows Scynexis to prioritize pipeline assets while GSK aims to revive a struggling antifungal, signaling a changing landscape in biotech commercialization.

Viking Therapeutics is challenging the weight loss drug landscape with VK2735, a dual GIP/GLP-1 agonist. Rapid enrollment in its Phase 3 trial signals strong demand and positions the company as a potential competitor to Wegovy and Zepbound.

Protara Therapeutics is set to release interim data on TARA-002, a novel cell therapy targeting pediatric lymphatic malformations. Experts suggest this could disrupt the rare disease treatment landscape.

The European Commission has approved Insmed’s BRINSUPRI, the first targeted therapy for non-cystic fibrosis bronchiectasis in the EU. This marks a significant step forward for the 600,000+ affected Europeans.